Cellectis S.A. financial data

Symbol
CLLS on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
8 Rue De La Croix Jarry, Paris, Lle De France, France
Fiscal year end
December 31
Latest financial report
6-K/A - Q2 2024 - Sep 11, 2024

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 71.8M shares +57.1%

Income Statement

Label TTM Value / Value Unit Change %
Research And Development Expense 23.5M USD +5.94%

Balance Sheet

Label TTM Value / Value Unit Change %
Assets 407M USD +78.8%
Liabilities 259M USD